Xu X et al., 2022-06-22: Study of methylene blue phototherapy driving dendritic cell maturation and antigen presentation, with in-vitro and in-vivo experiments – the record states in vivo without naming the species.
Moreover, the MB@OVA/PPY NPs synergized with DAMPs to promote the maturation and improve the antigen presentation ability of DCs in vitro and in vivo.
Xu X et al., 2022-06-22: Study of methylene blue phototherapy driving dendritic cell maturation and antigen presentation, with in-vitro and in-vivo experiments – the record states in vivo without naming the species. C6 Xu 2022. Study type: in vitro plus in vivo mouse tumour study. Country: China (Jiangsu). Agent: MB@OVA/PPY nanoparticles, 808 nm and 660 nm laser. Funder: Changzhou Science and Technology Bureau (CJ20200108), Jiangsu Natural Science Foundation (SBK2020022937), Zhenjiang programme (SH2019002), Jiangsu university major project (19KJA150004). Conflicts: none. Comparator: photothermal/PDT arms without antigen. NOTE: the immune effect depends on co-delivered ovalbumin antigen, not methylene blue alone. Study type: animal.
